LGND vs. DVAX, MNKD, IRWD, INVA, OPK, GERN, ARCT, PRAX, NRIX, and CMPS
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Dynavax Technologies (DVAX), MannKind (MNKD), Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), OPKO Health (OPK), Geron (GERN), Arcturus Therapeutics (ARCT), Praxis Precision Medicines (PRAX), Nurix Therapeutics (NRIX), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry.
Ligand Pharmaceuticals (NASDAQ:LGND) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.
Ligand Pharmaceuticals has higher earnings, but lower revenue than Dynavax Technologies. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
Ligand Pharmaceuticals has a net margin of 79.30% compared to Dynavax Technologies' net margin of 3.91%. Ligand Pharmaceuticals' return on equity of 8.52% beat Dynavax Technologies' return on equity.
91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are held by institutional investors. 10.4% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of Dynavax Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Ligand Pharmaceuticals currently has a consensus price target of $116.33, indicating a potential upside of 35.18%. Dynavax Technologies has a consensus price target of $25.33, indicating a potential upside of 128.02%. Given Dynavax Technologies' higher probable upside, analysts clearly believe Dynavax Technologies is more favorable than Ligand Pharmaceuticals.
Ligand Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
In the previous week, Dynavax Technologies had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 21 mentions for Dynavax Technologies and 17 mentions for Ligand Pharmaceuticals. Dynavax Technologies' average media sentiment score of 0.64 beat Ligand Pharmaceuticals' score of 0.28 indicating that Dynavax Technologies is being referred to more favorably in the news media.
Ligand Pharmaceuticals received 65 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 69.96% of users gave Ligand Pharmaceuticals an outperform vote while only 65.82% of users gave Dynavax Technologies an outperform vote.
Summary
Ligand Pharmaceuticals beats Dynavax Technologies on 10 of the 17 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
